Management of Hyperuricemia in Patients on Antihypertensive Medications
Antihypertensive Medication Selection
- Loop diuretics can cause hyperuricemia and increase gout risk in heart failure patients 1
- Losartan is the preferred antihypertensive agent for patients with gout or hyperuricemia due to its unique uric acid-lowering properties through uricosuric effects 2 3
When to Initiate Urate-Lowering Therapy
- Urate-lowering therapy is NOT recommended for asymptomatic hyperuricemia (serum urate >6.8 mg/dL without gout symptoms), even in hypertensive patients 4 5
- The number needed to treat is 24 patients for 3 years to prevent a single gout flare, and only 20% of patients with serum urate >9 mg/dL develop gout within 5 years 4 5
Urate-Lowering Therapy Protocol
- Allopurinol is the preferred first-line urate-lowering agent for all patients, including those with moderate-to-severe chronic kidney disease 4 6
- Target serum urate <6 mg/dL for maintenance therapy in most patients 4 7
- Target <5 mg/dL (300 μmol/L) for severe gout with tophi, chronic arthropathy, or frequent attacks to hasten crystal dissolution 7
Alternative and Combination Strategies
- Febuxostat can be substituted for allopurinol in cases of drug intolerance, adverse events, or failure to achieve target after maximal dose titration 6 7
- Add a uricosuric agent (probenecid, fenofibrate, or losartan) to a xanthine oxidase inhibitor if target serum urate is not achieved with monotherapy 6 3 7
Common Pitfalls and Caveats
- Continue urate-lowering therapy during acute gout flares; do not discontinue 4
- In acute gout, use a short course of colchicine for pain and inflammation; NSAIDs should be avoided if possible in symptomatic hypertensive patients 1
- Prophylactic therapy with allopurinol is recommended to prevent recurrence in heart failure patients prone to hyperuricemia from loop diuretics 1
- The American College of Cardiology recommends monitoring serum uric acid levels regularly to guide dose titration and ensure target achievement 9 10